Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. Cosmo Pharmaceuticals N.V.
  6. News
  7. Übersicht
    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(A2AJ68)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen

EQS-Adhoc : Halbjahresbericht 2021 von Cosmo -2-

30.07.2021 | 07:01

Disclaimer Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements. This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933. This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus. This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents. This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/ EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities. ----------------------------------------------------------------------------------------------------------------------- Ende der Ad-hoc-Mitteilung -----------------------------------------------------------------------------------------------------------------------

Sprache:      Deutsch 
Unternehmen:  Cosmo Pharmaceuticals N.V. 
              Riverside 2, Sir John Rogerson's 
              Dublin 2 Dublin 
              Irland 
Telefon:      + 353 1 817 0370 
E-Mail:       info@cosmopharma.com 
Internet:     https://www.cosmopharma.com/ 
ISIN:         NL0011832936 
Börsen:       SIX Swiss Exchange 
EQS News ID:  1222892 
 
Ende der Mitteilung EQS Group News-Service 
=------------ 

1222892 2021-07-30 GMT/BST

 
Bildlink: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1222892&application_name=news 
 

(END) Dow Jones Newswires

July 30, 2021 01:00 ET (05:00 GMT)

Alle Nachrichten zu COSMO PHARMACEUTICALS N.V.
04.10.Cassiopea-Aktien reagieren freundlich auf Cosmo-Offerte
AW
04.10.Pharmafirma Cosmo will Cassiopea vollständig übernehmen
AW
04.10.Cosmo Pharmaceuticals leitet öffentliches Tauschangebot für Cassiopea ein
MT
04.10.COSMO PHARMACEUTICALS N : Pharmafirma Cosmo will Cassiopea vollständig übernehmen
RE
04.10.Cosmo pharmaceuticals n.v. lanciert -2-
DJ
04.10.Cosmo pharmaceuticals n.v. lanciert öffentliches umtauschangebot zur übernahme von cass..
DJ
04.10.Cosmo pharmaceuticals n.v. lanciert öffentliches umtauschangebot zur übernahme von cass..
DP
30.07.Cosmo kündigt nach Halbjahresverlust Gewinn für 2021 an
AW
30.07.Halbjahresbericht 2021 von Cosmo
DP
30.07.EQS-ADHOC : Halbjahresbericht 2021 von Cosmo
DJ
Weitere Nachrichten
News auf Englisch zu COSMO PHARMACEUTICALS N.V.
04.10.COSMO PHARMACEUTICALS N : Initiates Public Exchange Offer For Cassiopea
MT
04.10.Cosmo pharmaceuticals n.v. launches -2-
DJ
04.10.Cosmo pharmaceuticals n.v. launches public exchange offer to acquire cassiopea s.p.a.
DJ
30.07.COSMO PHARMACEUTICALS N : Logs Widened H1 Loss On Higher Expenses
MT
30.07.EQS-ADHOC : Cosmo Half-Year Report 2021
DJ
30.07.Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
29.07.EQS-ADHOC : Cassiopea Announces Results for First Half of 2021
DJ
26.07.CASSIOPEA S P A : Enters License, Supply Deals for Acne Treatment in North America
MT
26.07.EQS-ADHOC : Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License and Supply ..
DJ
28.05.COSMO PHARMACEUTICALS N : ' Shareholders approve all Agenda Items at Annual General Meetin..
EQ
Weitere Nachrichten auf Englisch
Analystenempfehlungen zu COSMO PHARMACEUTICALS N.V.
Mehr Empfehlungen
Finanzkennziffern
Umsatz 2021 61,3 Mio 71,3 Mio -
Nettoergebnis 2021 6,00 Mio 6,97 Mio -
Nettoliquidität 2021 42,1 Mio 48,9 Mio -
KGV 2021 164x
Dividendenrendite 2021 -
Marktkapitalisierung 955 Mio 1 115 Mio -
Marktkap. / Umsatz 2021 14,9x
Marktkap. / Umsatz 2022 11,2x
Mitarbeiterzahl 276
Streubesitz 45,1%
Chart COSMO PHARMACEUTICALS N.V.
Dauer : Zeitraum :
Cosmo Pharmaceuticals N.V. : Chartanalyse Cosmo Pharmaceuticals N.V. | MarketScreener
Vollbild-Chart
Chartanalyse-Trends COSMO PHARMACEUTICALS N.V.
KurzfristigMittelfristigLangfristig
TrendsFallendFallendFallend
Ergebnisentwicklung
Analystenschätzung
Verkaufen
Kaufen
Durchschnittl. Empfehlung KAUFEN
Anzahl Analysten 2
Letzter Schlusskurs 66,54 €
Mittleres Kursziel 100,77 €
Abstand / Durchschnittliches Kursziel 51,4%
Verlauf des Gewinns je Aktie
Vorstände und Aufsichtsräte
Alessandro Della Chà Chief Executive Officer & Executive Director
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Mauro Severino Ajani Executive Chairman
Davide Malavasi Director-Qualified Person & Technical
Stefano Selva Chief Scientific Officer
Branche und Wettbewerber
01.01.Wert (M$)
COSMO PHARMACEUTICALS N.V.-16.12%1 111
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952